Question 59

Therapeutic duplication concern with atorvastatin and Zocor.

Therapeutic duplication occurs when a patient is prescribed multiple medications that have similar effects, which can lead to increased risk of side effects and potential toxicity. Atorvastatin and Zocor, which is a brand name for simvastatin, are both statins used to lower cholesterol levels, hence presenting a therapeutic duplication concern.

A) Cardizem

Cardizem, which contains diltiazem, is a calcium channel blocker used primarily for hypertension and angina. It does not share the same mechanism of action as atorvastatin and does not pose a therapeutic duplication concern in this context.

B) Lopressor

Lopressor, the brand name for metoprolol, is a beta-blocker used to treat high blood pressure and heart issues. Like Cardizem, it acts differently from atorvastatin and does not create a therapeutic duplication issue.

C) Zocor

Zocor is a brand name for simvastatin, which, like atorvastatin, is a statin that lowers cholesterol. The concurrent use of atorvastatin and Zocor leads to therapeutic duplication, as both drugs have similar effects and can increase the risk of adverse effects associated with statin use.

D) Norvasc

Norvasc, which contains amlodipine, is another calcium channel blocker used for hypertension and angina. It does not have a similar action to atorvastatin and therefore does not present a therapeutic duplication concern.

Conclusion

The therapeutic duplication concern arises specifically with atorvastatin and Zocor, as both medications serve the same purpose of cholesterol management. The presence of two statins can elevate the risk of side effects without providing additional therapeutic benefits, making the other options irrelevant in this context. Understanding these interactions is crucial for safe medication management.